- $1.59bn
- $1.37bn
- $361.05m
- 79
- 31
- 43
- 49
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.52 | ||
Price to Tang. Book | 6.28 | ||
Price to Free Cashflow | 46.31 | ||
Price to Sales | 4.39 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -8.14% | ||
Return on Equity | -7.02% | ||
Operating Margin | -23.76% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 120.37 | 117.48 | 219.51 | 296.54 | 361.05 | 397.84 | 443.37 | 31.45% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Directors
- Bonnie Anderson CHM (63)
- Marc Stapley CEO (51)
- Rebecca Chambers CFO (43)
- Tina Nova CEX (67)
- Robert Brainin EVP (50)
- Bill Zondler SVP
- Beverly Alley CAO (58)
- Giulia Kennedy CSO (61)
- John Bishop LED (76)
- Muna Bhanji IND (58)
- Frederick Cohen IND (64)
- Karin Eastham IND (71)
- Robert Epstein IND (66)
- Kevin Gordon IND (58)
- Jens Holstein IND (57)
- Evan Jones IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 15th, 2006
- Public Since
- October 30th, 2013
- No. of Shareholders
- 38
- No. of Employees
- 815
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 78,436,369
- Address
- 6000 Shoreline Court, Suite 300, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.veracyte.com/
- Phone
- +1 6502436300
- Auditors
- Ernst & Young LLP
Upcoming Events for VCYT
Veracyte Inc Annual Shareholders Meeting
Q2 2024 Veracyte Inc Earnings Release
Similar to VCYT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 19:23 UTC, shares in Veracyte are trading at $20.23. This share price information is delayed by 15 minutes.
Shares in Veracyte last closed at $20.23 and the price had moved by -11.27% over the past 365 days. In terms of relative price strength the Veracyte share price has underperformed the S&P500 Index by -28.34% over the past year.
The overall consensus recommendation for Veracyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Veracyte does not currently pay a dividend.
Veracyte does not currently pay a dividend.
Veracyte does not currently pay a dividend.
To buy shares in Veracyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $20.23, shares in Veracyte had a market capitalisation of $1.59bn.
Here are the trading details for Veracyte:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VCYT
Based on an overall assessment of its quality, value and momentum Veracyte is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Veracyte is $31.50. That is 55.71% above the last closing price of $20.23.
Analysts covering Veracyte currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veracyte. Over the past six months, its share price has underperformed the S&P500 Index by -18.85%.
As of the last closing price of $20.23, shares in Veracyte were trading -17.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Veracyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Veracyte's management team is headed by:
- Bonnie Anderson - CHM
- Marc Stapley - CEO
- Rebecca Chambers - CFO
- Tina Nova - CEX
- Robert Brainin - EVP
- Bill Zondler - SVP
- Beverly Alley - CAO
- Giulia Kennedy - CSO
- John Bishop - LED
- Muna Bhanji - IND
- Frederick Cohen - IND
- Karin Eastham - IND
- Robert Epstein - IND
- Kevin Gordon - IND
- Jens Holstein - IND
- Evan Jones - IND